Predicting Immunotherapy Response in Bladder Cancer

ROBERT DREICER, MD

Thursday, March 21, 2019

When it comes to predicting response to checkpoint inhibitors for patients with urothelial carcinoma, PD-L1 status may not be the most accurate factor, explained Robert Dreicer, MD, deputy director of UVA Cancer Center, director of solid tumor oncology within the division of hematology/oncology and is a professor of medicine and urology at the University of Virginia.

PD-L1 is not the most reliable predictor because there are many patients whose tumors are not PD-L1 positive who still respond to immunotherapy. More research in this field is still warranted.

Discussions >>

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.

Related Videos

Making Cold Breast Cancer Tumors Hot

By: Hope S. Rugo, MD, FASCO

Cytoreducive Nephrectomy in RCC: Challenges Nurses Face

By: Ziad Bakouny, MD, MSc

Nurse Offers Advice on Discussing AEs With Patients

By: Kathleen Madden, MSN, RN, APHN, AOCNP, FNP-BC